Bristol-Myers Squibb Lowers FY2026 Adj EPS Guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 Est; Raises FY2026 Sales Guidance from $49.000B-$50.000B to $49.750B-$50.250B vs $49.886B Est

Loading news article.

Bristol-Myers Squibb Lowers FY2026 Adj EPS Guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 Est; Raises FY2026 Sales Guidance from $49.000B-$50.000B to $49.750B-$50.250B vs $49.886B Est | WAPE

Bristol-Myers Squibb Lowers FY2026 Adj EPS Guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 Est; Raises FY2026 Sales Guidance from $49.000B-$50.000B to $49.750B-$50.250B vs $49.886B Est

Article summary

Related companies

Comments —